Site Search

Search market news

Find public news by keyword, exact ticker, category and date.

News by ticker →AAPL news SPY news Earnings

News Feed

1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.

News 2026-09-21 10:44 UTC

NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ⠀ · CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. · Trial used a 1.0 mg dose of each CagriSema component.

NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ⠀ • CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. • Trial used a 1.0 mg dose of each CagriSema component.

Search market news

Matching instruments

NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ⠀ · CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. · Trial used a 1.0 mg dose of each CagriSema component.